WeVote

Bill

Bill

HB 830

Health Insurance - Genetic Testing and Cancer Imaging - Required Coverage

2025 Regular Session Introduced by Tiffany Alston and 27 co-sponsors

Maryland requires insurers to cover genetic cancer risk testing and advanced imaging without prior authorization, expanding preventive access but potentially raising insurance costs.

Referred Finance
0
WeVote Research Nonpartisan
Bill Summary · HB 830

Legislative bill overview

HB 830 mandates that Maryland health insurance plans cover genetic testing for cancer risk assessment and advanced cancer imaging technologies without prior authorization requirements. The bill aims to ensure timely access to preventive and diagnostic procedures that can identify cancer earlier, potentially improving health outcomes for insured individuals.

Why is this important

Early cancer detection significantly improves survival rates and treatment outcomes, but insurance barriers can delay access to necessary screening. By removing prior authorization requirements and mandating coverage, the bill addresses potential gaps where patients might avoid these tests due to cost or administrative hurdles, particularly affecting populations with higher cancer risk factors.

Potential points of contention

  • Insurance cost increases: Mandated coverage of genetic testing and advanced imaging without prior authorization may increase premiums for all policyholders, raising affordability concerns for those who may never use these services
  • Prior authorization removal: Eliminating prior authorization could lead to overutilization of expensive imaging technologies, increasing overall healthcare costs without clinical benefit verification
  • Genetic testing scope ambiguity: The bill's definition of which genetic tests are covered and for whom (risk factors, family history requirements) may be insufficiently detailed, creating implementation and coverage dispute challenges

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.